Mutually beneficial relationship between Sandoz and Pear Therapeutics highlights the value of a digital therapeutics partnership

July 2, 2019 | Case Study

As Lux continues to recommend that clients engage with digital therapeutics, it is important to consider how to assess digital therapeutics companies as partnership or investment opportunities, especially in terms of how they are navigating the current healthcare landscape. One of the ways digital therapeutics companies are doing this is through partnership with pharmaceutical companies. Here, we highlight Pear Therapeutics' partnership with Sandoz, the generic arm of Novartis. Through this partnership, Sandoz is adopting a strategy to demonstrate an effort toward mitigating some of the negative impacts of the abuse of some opioid products using Pear Therapeutics' reSET and reSET-O products. In turn, Sandoz is negotiating reimbursement with payers and subsidizing some of the use of the product to in order to drive physician adoption, gaining the longitudinal data necessary to drive broader insurance payer reimbursement.